Table 1. Morbidity and mortality from cerebrovascular disease according to randomised treatment (5 vs 2 years of tamoxifen) for the entire follow-up (>2 years after start of treatment), during treatment (2–5 years) and after treatment (>5 years).

		Number of events
	Years since start of treatment	2-year group (n=2114)	5-year group (n=2036)	Hazard ratio (5 vs 2 years) (95% CI)	P-valuea	P diff.
Morbidity
Cerebrovascular diseases (430–8)b	>2	213	198	0.89 (0.73–1.08)	0.23
	2–5	27	44	1.70 (1.05–2.75)	0.030
	>5	186	154	0.78 (0.63–0.96)	0.020	0.0033
Stroke (431, 433, 434, 436)b	>2	167	148	0.84 (0.67–1.05)	0.13
	2–5	20	33	1.72 (0.99–3.00)	0.056
	>5	147	115	0.73 (0.57–0.93)	0.011	0.0056
Ischaemic stroke (433, 434)b	>2	115	119	0.98 (0.76–1.27)	0.89
	2–5	13	26	2.10 (1.08–4.09)	0.029
	>5	102	93	0.85 (0.64–1.12)	0.25	0.014
Haemorrhagic stroke (431)b	>2	27	22	0.76 (0.43–1.33)	0.34
	2–5	5	6	1.22 (0.37–3.99)	0.75
	>5	22	16	0.66 (0.35–1.26)	0.21	0.37
Other and unspecified cerebrovascular	>2	76	79	0.99 (0.72–1.36)	0.97
diseases (430, 432, 435, 437, 438)b	2–5	9	16	1.85 (0.82–4.19)	0.14
	>5	67	63	0.88 (0.63–1.25)	0.48	0.10
TIA (435)b	>2	14	17	1.22 (0.60–2.47)	0.59
	2–5	4	8	2.07 (0.62–6.86)	0.24
	>5	10	9	0.88 (0.36–2.18)	0.79	0.27
Mortality
Cerebrovascular diseases (430–8)b	>2	62	50	0.75 (0.52–1.10)	0.14
	2–5	4	12	3.18 (1.03–9.87)	0.045
	>5	58	38	0.60 (0.40–0.90)	0.014	0.0066

Abbreviations: CI=confidence interval; P diff.=P-value for difference in HR between the time-periods during and after treatment.

^aTwo-sided Wald test.

^bNinth International Classification of Diseases code numbers.